Evidence map›Paper›PMID 33643576›Full record

ArticleIranian journal of basic medical sciences2021

Masoumeh Shirmohammadi, Hoorieh Soleimanjahi, Zahra Kianmehr, Hesam Karimi, Susan Kaboudanian Ardestani

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Masoumeh ShirmohammadiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Hoorieh SoleimanjahiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Zahra KianmehrDepartment of Biochemistry, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Hesam KarimiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Susan Kaboudanian ArdestaniImmunology Lab, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Tarbiat Modares University · IRIslamic Azad University North Tehran Branch · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesHuman papillomavirus (HPV) is a primary contributing agent of cervical cancer. Eradication of HPV-related infections requires therapeutic strategies. We used MATERIALS AND

methodsFor evaluation of the

resultsFindings indicated that vaccination with pcDNA3-E7 or pcDNA3-L1 alone could induce strong cellular immune responses, but stronger antigen-specific T-cell immune responses were shown by co-administration of HPV16 E7 and HPV16 L1 DNA vaccines along with R-LPS adjuvant.

conclusionOverall,

Indexed as

AdjuvantBrucella abortus RB51Cervical cancerDNA vaccinesHuman papillomavirusLipopolysaccharide

Identifiers

PMID33643576
PMCPMC7894634
OpenAlexW3134379867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.